Research programme: microsomal prostaglandin E synthase-1 inhibitors - Angelini

Drug Profile

Research programme: microsomal prostaglandin E synthase-1 inhibitors - Angelini

Alternative Names: AF3485; Eicosanoid inhibitors; Eicosanoid modulators

Latest Information Update: 25 Jul 2011

Price : $50

At a glance

  • Originator Angelini Group
  • Class
  • Mechanism of Action Prostaglandin-E synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Cancer; Inflammatory pain

Most Recent Events

  • 25 Jul 2011 Programme is still in preclinical development for Inflammatory pain in Italy
  • 08 Apr 2008 Preclinical trials in Inflammatory pain in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top